| Title |
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, September 2017
|
| DOI | 10.1007/s00259-017-3817-y |
| Pubmed ID | |
| Authors |
Clemens Kratochwil, Karl Schmidt, Ali Afshar-Oromieh, Frank Bruchertseifer, Hendrik Rathke, Alfred Morgenstern, Uwe Haberkorn, Frederik L. Giesel |
| Abstract |
PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA). In this work, we estimate the radiation dosimetry for this ligand labeled with the alpha-emitter (213)Bi. Three patients with metastatic prostate cancer underwent PET scans 0.1 h, 1 h, 2 h, 3 h, 4 h and 5 h after injection of (68)Ga-PSMA-617. Source organs were kidneys, liver, spleen, salivary glands, bladder, red marrow and representative tumor lesions. The imaging nuclide (68)Ga was extrapolated to the half-life of (213)Bi. The residence times of (213)Bi were forwarded to the instable daughter nuclides. OLINDA was used for dosimetry calculation. Results are discussed in comparison to literature data for (225)Ac-PSMA-617. Assuming a relative biological effectiveness of 5 for alpha radiation, the dosimetry estimate revealed equivalent doses of mean 8.1 Sv RBE5/GBq for salivary glands, 8.1 Sv RBE5/GBq for kidneys and 0.52 Sv RBE5/GBq for red marrow. Liver (1.2 Sv RBE5/GBq), spleen (1.4 Sv RBE5/GBq), bladder (0.28 Sv RBE5/GBq) and other organs (0.26 SvRBE5/GBq) were not dose-limiting. The effective dose is 0.56 Sv RBE5/GBq. Tumor lesions were in the range 3.2-9.0 SvRBE5/GBq (median 7.6 SvRBE5/GBq). Kidneys would limit the cumulative treatment activity to 3.7 GBq; red marrow might limit the maximum single fraction to 2 GBq. Despite promising results, the therapeutic index was inferior compared to (225)Ac-PSMA-617. Dosimetry of (213)Bi-PSMA-617 is in a range traditionally considered reasonable for clinical application. Nevertheless, compared to (225)Ac-PSMA-617, it suffers from higher perfusion-dependent off-target radiation and a longer biological half-life of PSMA-617 in dose-limiting organs than the physical half-life of (213)Bi, rendering this nuclide as a second choice radiolabel for targeted alpha therapy of prostate cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 113 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 16% |
| Student > Master | 17 | 15% |
| Student > Ph. D. Student | 13 | 12% |
| Student > Bachelor | 12 | 11% |
| Unspecified | 10 | 9% |
| Other | 13 | 12% |
| Unknown | 30 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 19% |
| Chemistry | 17 | 15% |
| Unspecified | 10 | 9% |
| Physics and Astronomy | 9 | 8% |
| Engineering | 6 | 5% |
| Other | 19 | 17% |
| Unknown | 31 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2023.
All research outputs
#3,243,217
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#327
of 3,083 outputs
Outputs of similar age
#59,477
of 317,354 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#3
of 43 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.